Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi Sells 3,128 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,128 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $6.42, for a total transaction of $20,081.76. Following the completion of the sale, the chief technology officer now owns 1,759,648 shares of the company’s stock, valued at approximately $11,296,940.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Sight Sciences Stock Performance

Shares of SGHT stock opened at $6.19 on Thursday. The company has a 50-day moving average of $6.07 and a two-hundred day moving average of $5.26. Sight Sciences, Inc. has a 1-year low of $1.04 and a 1-year high of $9.31. The company has a quick ratio of 12.42, a current ratio of 13.01 and a debt-to-equity ratio of 0.31.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). Sight Sciences had a negative return on equity of 44.45% and a negative net margin of 67.18%. The company had revenue of $19.27 million for the quarter, compared to analysts’ expectations of $18.34 million. Equities analysts anticipate that Sight Sciences, Inc. will post -1.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

A number of institutional investors have recently modified their holdings of SGHT. UBS Group AG grew its holdings in shares of Sight Sciences by 20,282.6% in the fourth quarter. UBS Group AG now owns 2,895,958 shares of the company’s stock valued at $14,943,000 after purchasing an additional 2,881,750 shares in the last quarter. Jackson Square Partners LLC increased its position in shares of Sight Sciences by 12.0% during the fourth quarter. Jackson Square Partners LLC now owns 1,629,746 shares of the company’s stock worth $8,409,000 after acquiring an additional 174,737 shares during the period. Vanguard Group Inc. increased its position in shares of Sight Sciences by 5.5% during the first quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock worth $8,218,000 after acquiring an additional 81,768 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in shares of Sight Sciences by 25.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after acquiring an additional 76,549 shares in the last quarter. Finally, RTW Investments LP purchased a new position in Sight Sciences in the fourth quarter valued at $850,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on SGHT shares. Piper Sandler reaffirmed a “neutral” rating and issued a $6.00 target price (up from $5.00) on shares of Sight Sciences in a research note on Friday, May 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, Sight Sciences currently has a consensus rating of “Hold” and a consensus target price of $4.70.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.